Nel ASA

Capital/Financing Update • Jan 10, 2014

DiaGenic reduces its payment obligations

DiaGenic reduces its payment obligations

It is referred to the announcement made on 4 December 2014 regarding the

financial situation of DiaGenic ASA.

DiaGenic has entered into an agreement with its largest creditor that

significantly reduces DiaGenic's financial liabilities going forward.

The agreement includes a final payment of NOK 1.5 million to DiaGenic's

landlord in exchange for the termination of a long-term facility lease

contract. The total estimated liability for the facility lease per 30

September 2013 was reported in the third quarter report 2013 to be NOK

5.8 million.

To enable an earlier termination of the facility lease, Tycoon

Industrier AS, one of DiaGenic's larger shareholders, has entered an on

demand guarantee for invalidation of NOK 1.5 million with DiaGenic's

landlord. DiaGenic has agreed to compensate Tycoon Industries AS with

NOK 100,000 for putting up the guarantee.

In addition, financial liabilities for clinical samples not recorded in

the financial statements have been reduced by NOK 1.2 million since the

third quarter report 2013.

DiaGenic's reduced payment obligations and cost base are important steps

to find a long term financial solution for the company's future

operations.

For more information, contact: Hanne Skaarberg Holen, Chairman of the

board, telephone: +47 9829 4591

About DiaGenic ASA

DiaGenic is an innovative Norwegian diagnostic company that seeks to

create value for patients, partners and investors by developing

innovative and patient friendly in vitro diagnostic (IVD) products for

early detection of diseases. The company's proprietary concept implies

that a disease evokes systemic responses in the blood unique for the

disease, and which can be measured by using a blood sample. DiaGenic is

a world leader in identifying gene expression signatures in blood and is

focused on the development of IVD biomarker products in the field of

Alzheimer's disease. The company protects its technology through an

extensive patent portfolio. DiaGenic is listed on the Oslo Stock

Exchange. For more information please visit: www.diagenic.com